Conservest Capital Advisors Inc. Trims Stake in VanEck Biotech ETF (NASDAQ:BBH)

Conservest Capital Advisors Inc. lowered its stake in shares of VanEck Biotech ETF (NASDAQ:BBH) by 3.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,683 shares of the company’s stock after selling 548 shares during the quarter. Conservest Capital Advisors Inc. owned about 0.72% of VanEck Biotech ETF worth $2,776,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of BBH. Truvestments Capital LLC bought a new stake in VanEck Biotech ETF during the third quarter worth about $44,000. FSA Wealth Management LLC bought a new stake in VanEck Biotech ETF during the third quarter worth about $54,000. Coastline Trust Co bought a new stake in VanEck Biotech ETF during the third quarter worth about $59,000. Wilmington Savings Fund Society FSB bought a new stake in VanEck Biotech ETF during the third quarter worth about $166,000. Finally, Commonwealth Retirement Investments LLC bought a new position in shares of VanEck Biotech ETF in the fourth quarter worth approximately $215,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Trading Up 1.1 %

Shares of NASDAQ BBH opened at $164.58 on Friday. The firm’s 50 day moving average price is $161.48 and its 200-day moving average price is $169.13. VanEck Biotech ETF has a 52-week low of $151.35 and a 52-week high of $183.64.

VanEck Biotech ETF Dividend Announcement

The company also recently announced a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were paid a $1.2517 dividend. The ex-dividend date was Monday, December 23rd.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.